Kirkland Helps Akorn Clinch $440M Deal For Niche Drugmaker
Akorn Inc. on Friday added to a lengthy list of moves cashing in on a tide of deal-making, unveiling its $440 million acquisition of private equity-backed VersaPharm Inc., which produces generic-drug...To view the full article, register now.
Already a subscriber? Click here to view full article